Back to search results

T Cell Therapy for COVID-19 Prevention After Stem Cell Transplant

This study is testing a treatment called coronavirus-specific T cell (CST) therapy to see if it can safely prevent SARS-CoV-2 (the virus that causes COVID-19) infection in people who have recently had a hematopoietic stem cell transplant (HSCT). These patients often have weakened immune systems. You would receive CSTs, which are special immune cells from your stem cell donor, to help your body fight off the virus. The study is looking for serious side effects from the infusion, severe graft-versus-host disease (a condition where donor cells attack your body), and severe inflammatory reactions within 45 days of receiving the CSTs. This study is open to people aged 2 to 80 years old who are between 28 days and 4 months after their HSCT and have not tested positive for SARS-CoV-2. The study is currently recruiting participants.

Study design
This is an open-label study, meaning you and your doctors will know which treatment you are receiving. It will enroll 24 participants across different age groups to test three different doses of CSTs.
What's involved
Participants will receive one dose of CSTs. Safety will be monitored for 45 days after the infusion.
Compensation
Not stated in the trial record.
Follow-up
You will be followed for 45 days after receiving the CST infusion to check for any side effects or complications.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05141058

T Cell Therapy Opposing Novel COVID-19 Infection in Immunocompromised Patients

Recruiting
PHASE1Ages 2–80InterventionalPrevention
Children's National Research Institute
~24 participants
Updated 2026-03-12 on ClinicalTrials.gov
What's tested:Coronavirus-specific T cell (CST)

At a glance

Recruiting sites
2 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Incidence of grade ≥3 infusion-related Adverse Events (AEs)
Measured over Within 45 days of CST infusion
+3 more outcomes measured

Conditions

SARS-CoV-2 Infection

Explore related trials

COVID-19 Infection

Where it's being run

2 sites across 2 states
District of Columbia1
Maryland1

Who to contact

Susan Conway, MD
[email protected]
202-476-5845
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

What this trial measures

  • Incidence of grade ≥3 infusion-related Adverse Events (AEs)Within 45 days of CST infusion

    Number of patients with grade ≥3 infusion-related AEs at 45 days of following CST infusion.

  • Incidence of acute Graft Vs Host Disease (aGVHD) grade ≥3Within 45 days of CST infusion

    Number of patients with aGVHD grade ≥3 within 45 days of CST infusion.

  • Incidence of Systemic Inflammatory Response Syndrome (SIRS) or CRSWithin 45 days of CST infusion

    Number of patients with systemic Inflammatory Response Syndrome (SIRS) or CRS

  • Incidence of Multi-System Inflammatory Syndrome (MIS)Within 45 days of CST infusion

    Number of patients with MIS